Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee.

Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Review.

PMID:
31050216
2.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
3.

Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.

Leong TL, Gayevskiy V, Steinfort DP, De Massy MR, Gonzalez-Rajal A, Marini KD, Stone E, Chin V, Havryk A, Plit M, Irving LB, Jennings BR, McCloy RA, Jayasekara WSN, Alamgeer M, Boolell V, Field A, Russell PA, Kumar B, Gough DJ, Szczepny A, Ganju V, Rossello FJ, Cain JE, Papenfuss AT, Asselin-Labat ML, Cowley MJ, Watkins DN.

Oncogene. 2019 Mar;38(10):1661-1675. doi: 10.1038/s41388-018-0536-1. Epub 2018 Oct 22.

PMID:
30348992
4.

Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System.

Wainer Z, Wright GM, Gough K, Daniels MG, Russell PA, Choong P, Conron M, Ball D, Solomon B.

Clin Lung Cancer. 2018 Nov;19(6):e933-e944. doi: 10.1016/j.cllc.2018.08.004. Epub 2018 Aug 22.

PMID:
30206043
5.

Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review.

Blaauwgeers H, Russell PA, Jones KD, Radonic T, Thunnissen E.

Lung Cancer. 2018 Sep;123:107-111. doi: 10.1016/j.lungcan.2018.07.017. Epub 2018 Jul 18. Review.

PMID:
30089579
6.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.

PMID:
29800747
7.

The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53.

Szczepny A, Carey K, McKenzie L, Jayasekara WSN, Rossello F, Gonzalez-Rajal A, McCaw AS, Popovski D, Wang D, Sadler AJ, Mahar A, Russell PA, Wright G, McCloy RA, Garama DJ, Gough DJ, Baylin SB, Burgess A, Cain JE, Watkins DN.

Oncogene. 2018 Apr;37(14):1939-1948. doi: 10.1038/s41388-017-0022-1. Epub 2018 Jan 25.

8.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

9.

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.

Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MHW, Boutros PC, Wright G, Barnett SA, Mariadason JM, John T.

Oncotarget. 2017 May 23;8(43):74036-74048. doi: 10.18632/oncotarget.18198. eCollection 2017 Sep 26.

10.

De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.

Thai A, Chia PL, Russell PA, Do H, Dobrovic A, Mitchell P, John T.

Intern Med J. 2017 Sep;47(9):1071-1074. doi: 10.1111/imj.13531.

PMID:
28891180
11.

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM.

Med Oncol. 2017 Sep 6;34(10):175. doi: 10.1007/s12032-017-1031-1.

PMID:
28879441
12.

Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.

Russell PA, Rogers TM, Solomon B, Alam N, Barnett SA, Rathi V, Williams RA, Wright GM, Conron M.

Pathology. 2017 Oct;49(6):604-610. doi: 10.1016/j.pathol.2017.07.002. Epub 2017 Aug 12.

PMID:
28811082
13.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

14.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

15.

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.

Weeden CE, Holik AZ, Young RJ, Ma SB, Garnier JM, Fox SB, Antippa P, Irving LB, Steinfort DP, Wright GM, Russell PA, Ritchie ME, Burns CJ, Solomon B, Asselin-Labat ML.

Mol Cancer Ther. 2017 Aug;16(8):1610-1622. doi: 10.1158/1535-7163.MCT-17-0174. Epub 2017 Jun 13.

16.

Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.

Cooper WA, Russell PA, Cherian M, Duhig EE, Godbolt D, Jessup PJ, Khoo C, Leslie C, Mahar A, Moffat DF, Sivasubramaniam V, Faure C, Reznichenko A, Grattan A, Fox SB.

Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. doi: 10.1158/1078-0432.CCR-17-0151. Epub 2017 Apr 18.

17.

Is Mesothelioma in China Rare or Misdiagnosed?

John T, Russell PA, Thapa B.

J Thorac Oncol. 2017 Apr;12(4):607-609. doi: 10.1016/j.jtho.2017.02.004. No abstract available.

18.

Lung cancer and socio-economic status: inextricably linked to place of residence.

Denton EJ, Hart D, Russell PA, Wright G, Conron M.

Intern Med J. 2017 May;47(5):563-569. doi: 10.1111/imj.13376.

PMID:
28105777
19.

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.

Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, Dacic S, Lantuejoul S, Russell PA, den Bakker M, Botling J, Brambilla E, de Cuba E, Geisinger KR, Hiroshima K, Marchevsky AM, Minami Y, Moreira A, Nicholson AG, Yoshida A, Tsao MS, Warth A, Duhig E, Chen G, Matsuno Y, Travis WD, Butnor K, Cooper W, Mino-Kenudson M, Motoi N, Poleri C, Pelosi G, Kerr K, Aisner SC, Ishikawa Y, Buettner RH, Keino N, Yatabe Y, Noguchi M.

J Thorac Oncol. 2017 Feb;12(2):334-346. doi: 10.1016/j.jtho.2016.12.004. Epub 2016 Dec 18.

20.

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.

Chia PL, Russell PA, Scott AM, John T.

Expert Rev Anticancer Ther. 2016 Dec;16(12):1235-1245. Epub 2016 Oct 12. Review.

PMID:
27696931
21.

Impact of sex on prognostic host factors in surgical patients with lung cancer.

Wainer Z, Wright GM, Gough K, Daniels MG, Choong P, Conron M, Russell PA, Alam NZ, Ball D, Solomon B.

ANZ J Surg. 2017 Dec;87(12):1015-1020. doi: 10.1111/ans.13728. Epub 2016 Sep 14.

PMID:
27625078
22.

Nodular pulmonary light chain deposition disease.

Yee M, Delahunt B, Russell PA.

Pathology. 2016 Aug;48(5):515-8. doi: 10.1016/j.pathol.2016.04.012. Epub 2016 Jun 13. No abstract available.

PMID:
27306574
23.

Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre.

Denton EJ, Hart D, Wainer Z, Wright G, Russell PA, Conron M.

Intern Med J. 2016 Aug;46(8):946-54. doi: 10.1111/imj.13132.

PMID:
27177600
24.

Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Dobrovic A, Moore MM, McLachlan SA.

Pathology. 2016 Jan;48(1):17-24. doi: 10.1016/j.pathol.2015.11.002. Epub 2015 Dec 12.

PMID:
27020204
25.

Defining Measures of Quality in Lung Cancer Diagnosis and Staging.

Stirling RG, Russell PA, Wright GM.

Ann Thorac Surg. 2016 Apr;101(4):1628. doi: 10.1016/j.athoracsur.2015.09.051. No abstract available.

PMID:
27000594
26.
27.

IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.

Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, Rose-John S, Ruwanpura S, Jenkins BJ.

Cancer Res. 2016 Feb 15;76(4):866-76. doi: 10.1158/0008-5472.CAN-15-2388. Epub 2016 Jan 7.

28.

Electromagnetic Navigation Bronchoscopy-directed Pleural Tattoo to Aid Surgical Resection of Peripheral Pulmonary Lesions.

Tay JH, Wallbridge PD, Larobina M, Russell PA, Irving LB, Steinfort DP.

J Bronchology Interv Pulmonol. 2016 Jul;23(3):245-50. doi: 10.1097/LBR.0000000000000214.

PMID:
26496089
29.

The promise of lung master protocol for squamous cell carcinoma: one trial to rule them all, one trial to find them…?

Wright GM, Russell PA.

Ann Transl Med. 2015 Sep;3(15):219. doi: 10.3978/j.issn.2305-5839.2015.07.24.

30.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

31.

Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.

Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB.

Histopathology. 2016 Feb;68(3):367-77. doi: 10.1111/his.12765. Epub 2015 Aug 7.

PMID:
26118394
32.

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.

Rogers TM, Russell PA, Wright G, Wainer Z, Pang JM, Henricksen LA, Singh S, Stanislaw S, Grille J, Roberts E, Solomon B, Fox SB.

J Thorac Oncol. 2015 Apr;10(4):611-8. doi: 10.1097/JTO.0000000000000465.

33.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA, Thomas RK.

Genome Biol. 2015 Jan 5;16:7. doi: 10.1186/s13059-014-0558-0.

34.

Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens.

Leong TL, Marini KD, Rossello FJ, Jayasekara SN, Russell PA, Prodanovic Z, Kumar B, Ganju V, Alamgeer M, Irving LB, Steinfort DP, Peacock CD, Cain JE, Szczepny A, Watkins DN.

PLoS One. 2014 Sep 5;9(9):e106862. doi: 10.1371/journal.pone.0106862. eCollection 2014.

35.

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W.

Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31.

36.

Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH.

Russell PA, Yu Y, Young RJ, Conron M, Wainer Z, Alam N, Solomon B, Wright GM.

Mod Pathol. 2014 Dec;27(12):1621-31. doi: 10.1038/modpathol.2014.71. Epub 2014 Apr 25.

37.

Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Wright GM, Do H, Weiss J, Alam NZ, Rathi V, Walkiewicz M, John T, Russell PA, Dobrovic A.

Oncotarget. 2014 Apr 30;5(8):2107-15.

38.

The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma.

Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A, Russell PA.

J Thorac Oncol. 2014 May;9(5):654-63. doi: 10.1097/JTO.0000000000000150.

39.

CD74-NRG1 fusions in lung adenocarcinoma.

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK.

Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.

40.

Mobilization of viable tumor cells into the circulation during radiation therapy.

Martin OA, Anderson RL, Russell PA, Cox RA, Ivashkevich A, Swierczak A, Doherty JP, Jacobs DH, Smith J, Siva S, Daly PE, Ball DL, Martin RF, MacManus MP.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):395-403. doi: 10.1016/j.ijrobp.2013.10.033. Epub 2013 Dec 5.

PMID:
24315565
41.

EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma.

Russell PA, Yu Y, Do H, Clay TD, Moore MM, Wright GM, Conron M, Wainer Z, Dobrovic A, McLachlan SA.

Pathology. 2014 Jan;46(1):32-6. doi: 10.1097/PAT.0000000000000027.

PMID:
24300726
42.

First hand transplant procedure in Australia: outcome at 2 years.

Dwyer KM, Webb AR, Furniss HS, Anjou KE, Gibbs-Dwyer JM, McCombe DB, Grinsell DG, Dickinson GF, Williams RA, Russell PA, Scott DA, Baker C, Vogrin SJ, Langham RG, Opdam HI, Morrison WA.

Med J Aust. 2013 Aug 19;199(4):285-7. Review. No abstract available.

PMID:
23984788
43.

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS.

PLoS One. 2013 Jul 23;8(7):e67876. doi: 10.1371/journal.pone.0067876. Print 2013.

44.

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.

Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M, Conron M, Wright G, Watkins DN.

Thorax. 2013 Dec;68(12):1095-104. doi: 10.1136/thoraxjnl-2012-203021. Epub 2013 Jul 22.

45.

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B.

Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 Jun 7.

46.

Intravenous leiomyomatosis with intracardiac extension - a review of diagnosis and management with an illustrative case.

Clay TD, Dimitriou J, McNally OM, Russell PA, Newcomb AE, Wilson AM.

Surg Oncol. 2013 Sep;22(3):e44-52. doi: 10.1016/j.suronc.2013.03.004. Epub 2013 Apr 30. Review.

PMID:
23642379
47.

Overexpression of CD39 protects in a mouse model of preeclampsia.

McRae JL, Russell PA, Chia JS, Dwyer KM.

Nephrology (Carlton). 2013 May;18(5):351-5. doi: 10.1111/nep.12058.

PMID:
23600369
48.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

49.

Recurrent myocarditis--an important mimic of ischaemic myocardial infarction.

Xu B, Michael Jelinek V, Hare JL, Russell PA, Prior DL.

Heart Lung Circ. 2013 Jul;22(7):517-22. doi: 10.1016/j.hlc.2012.12.014. Epub 2013 Mar 5.

PMID:
23465652
50.

Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.

Young RJ, Lim AM, Angel C, Collins M, Deb S, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Russell PA, Wright G, McArthur GA, Fox SB, Rischin D, Solomon B.

Oral Oncol. 2013 Jun;49(6):576-81. doi: 10.1016/j.oraloncology.2013.01.006. Epub 2013 Feb 19.

PMID:
23434054

Supplemental Content

Loading ...
Support Center